Abstract: 3-Deazaneplanocin A (DZNep) is a carbocyclic nucleoside analog and a well-known inhibitor of S-adenosyl-L-homocysteine (SAH) hydrolase, as well as an indirect inhibitor of the histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2). Originally investigated for its broad-spectrum antiviral properties, DZNep has demonstrated significant efficacy against a variety of severe viral pathogens, including the Ebola virus (EBOV) and other viruses such as vesicular stomatitis virus (VSV). Its antiviral mechanism is primarily attributed to the inhibition of SAH hydrolase, which subsequently blocks the essential 5'-capping (ribose 2'-O-methylation) of viral mRNAs, leading to massive interferon-alpha production and viral suppression. Furthermore, its role as an epigenetic modulator via EZH2 inhibition has expanded its therapeutic potential into oncology and neuroinflammation. This review synthesizes the current understanding of DZNep's pharmacological activity, molecular mechanisms, structure-activity relationships, limitations, and future perspectives, with a primary focus on its antiviral applications and secondary insights from its epigenetic regulatory functions.
1. Introduction
The emergence and re-emergence of highly pathogenic viruses, such as the Ebola virus (EBOV), present significant global health threats. EBOV, a member of the Filoviridae family, causes severe hemorrhagic fever with case fatality rates ranging from 40% to 90% [1]. The urgent need for effective antiviral therapeutics has driven the exploration of various chemical compounds, among which nucleoside analogs have shown considerable promise. 3-Deazaneplanocin A (DZNep) is a prominent carbocyclic nucleoside analog that has garnered attention for its broad-spectrum antiviral activity and its role as an epigenetic modulator [1][2].
Initially identified as a potent inhibitor of S-adenosyl-L-homocysteine (SAH) hydrolase, DZNep was observed to induce a massive increase in interferon-alpha production in EBOV-infected mice, leading to protective antiviral effects [1]. Beyond virology, DZNep is recognized as an indirect inhibitor of the histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2), a key component of the Polycomb Repressive Complex 2 (PRC2). By inhibiting EZH2, DZNep prevents the trimethylation of histone 3 on lysine 27 (H3K27me3), thereby reactivating silenced genes. This epigenetic mechanism has positioned DZNep as a valuable compound in cancer therapy and the management of neuroinflammatory conditions [2][3][4]. This review comprehensively examines the multifaceted roles of DZNep, focusing on its antiviral efficacy, molecular mechanisms, and future therapeutic potential.
2. Pharmacological Activity
DZNep exhibits a diverse pharmacological profile, characterized by potent antiviral, anticancer, and anti-inflammatory activities.
Antiviral Activity: DZNep has demonstrated broad-spectrum antiviral efficacy, particularly against negative-strand RNA viruses. It is highly effective against EBOV, where it has been shown to protect infected mice from lethal challenges [1]. The compound is also active against the vesicular stomatitis virus (VSV), a rhabdovirus that shares replication strategies with filoviruses and often serves as a surrogate model for EBOV research [1]. The antiviral effects are closely linked to its ability to induce massive interferon-alpha production in vivo, which creates a robust antiviral state in the host [1].
Anticancer and Epigenetic Activity: In oncology, DZNep acts as a potent epigenetic therapeutic agent. It selectively induces apoptosis in BRCA1-deficient breast cancer cells by decreasing H3K27 trimethylation and downregulating PRC2 partners, including EZH2 and SUZ12 [5]. Molecular docking studies have shown that DZNep binds favorably within the JmjC domain of the histone demethylase KDM5B, indicating its potential to be repurposed as a KDM5B inhibitor for cancer therapy [2].
Anti-neuroinflammatory Activity: DZNep has shown neuroprotective effects in models of ischemic stroke and neuropathic pain. By inhibiting EZH2, DZNep reduces microglial pro-inflammatory activation (CD86+), decreases the production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and CXCL10), restricts STAT3 phosphorylation, and stimulates anti-inflammatory (CD206+) microglial polarization [3][4]. Intrathecal administration of DZNep in neuropathic rats successfully normalized EZH2 and H3K27me3 levels, attenuating mechanical allodynia and thermal hyperalgesia [4].
3. Molecular Mechanism of Action
The therapeutic effects of DZNep are mediated through two primary, interconnected biochemical pathways: the inhibition of SAH hydrolase and the indirect inhibition of EZH2 methyltransferase.
Inhibition of SAH Hydrolase (Antiviral Mechanism): DZNep is a potent inhibitor of S-adenosyl-L-homocysteine (SAH) hydrolase. During normal cellular methylation processes, S-adenosyl-L-methionine (SAM) donates a methyl group and is converted to SAH. SAH hydrolase is responsible for metabolizing SAH into adenosine and homocysteine. By inhibiting this enzyme, DZNep causes an intracellular accumulation of SAH. SAH acts as a potent feedback inhibitor of SAM-dependent methyltransferases [1][4]. In the context of viral infections like EBOV, this inhibition specifically blocks the 5'-capping (ribose 2'-O-methylation) of viral mRNAs. The unmethylated viral mRNA is recognized as "non-self" by host RNA sensors such as Mda5. Furthermore, the lack of methylation may prevent the release of mRNA from the (-)RNA/(+)RNA duplex, generating double-stranded RNA (dsRNA) molecules. These dsRNA molecules act as powerful inducers of the host immune response, leading to the massively increased interferon-alpha production observed in DZNep-treated models [1].
Indirect Inhibition of EZH2 (Epigenetic Mechanism): The accumulation of SAH induced by DZNep also globally inhibits histone methyltransferases, most notably EZH2, the catalytic subunit of the PRC2 complex [3][4]. EZH2 normally catalyzes the trimethylation of H3K27 (H3K27me3), leading to chromatin condensation and transcriptional repression of target genes. By indirectly inhibiting EZH2, DZNep reverses H3K27me3 accumulation, thereby reactivating silenced genes. In neuroinflammation, this prevents the suppression of anti-inflammatory mediators (such as SOCS3 and Nrf2) and microRNAs (like miR-124-3p and miR-146a-5p), ultimately mitigating microglial activation and neuropathic pain [4]. In cancer, this mechanism triggers differentiation and selective apoptosis in tumors reliant on EZH2 overexpression, such as BRCA1-mutated breast cancers [5].
4. Structure-Activity Relationship (SAR)
DZNep is a carbocyclic nucleoside analog featuring a planar bicyclic imidazo[4,5-c]pyridine ring template and a cyclopentenyl moiety [2]. Computational molecular docking studies have provided deep insights into how these structural features facilitate its interaction with target enzymes, particularly the JmjC domain of KDM5B.
The planar bicyclic imidazo[4,5-c]pyridine ring of DZNep is crucial for its binding affinity. It engages in π–π stacking interactions with aromatic residues such as Tyr488 and Phe496 (distance < 4.3 Å) within the α-ketoglutarate binding pocket of the enzyme [2]. A critical feature of DZNep's structure is the pyridine nitrogen, which acts as a metal chelator, forming a direct metal–ligand interaction with the catalytic Mn2+ ion (distance = 2.8 Å) in the active site [2]. Additionally, the C2 amino substituent forms hydrogen bonds with the backbone of Asn509, while the hydroxyl and hydroxymethyl substituents on the cyclopentenyl ring undergo hydrogen bonding with Gly426 and Ser495 (distance < 2.0 Å) [2]. These interactions yield a highly favorable LibDock score (131.60), demonstrating that the bicyclic purine-like template and the ability to chelate metal ions are vital structural determinants for its potent inhibitory activity [2].
5. Current Limitations
Despite its potent pharmacological activities, the clinical translation of DZNep faces several significant limitations:
- Lack of Specificity: Because DZNep targets SAH hydrolase, it causes a global accumulation of SAH, which inhibits a wide array of SAM-dependent methyltransferases. It is not a selective EZH2 antagonist; rather, it impedes all histone methylation globally, leading to off-target epigenetic effects [3][4].
- Toxicity and Adverse Effects: The global interference with methylation pathways results in poor clinical viability due to systemic toxicity. In animal models, DZNep has been associated with potential neurotoxicity, impaired neurogenesis, blood-brain barrier (BBB) disruption, anemia,
